SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91 | +5.8% | 752 | 0.0% | 0.00% | +100.0% |
| Q2 2023 | $86 | -17.3% | 752 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $104 | +7.2% | 752 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $97 | -99.9% | 752 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $83,000 | +48.2% | 752 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $56,000 | -5.1% | 752 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $59,000 | -13.2% | 752 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $68,000 | -2.9% | 752 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $70,000 | -10.3% | 752 | -24.8% | 0.00% | 0.0% |
| Q2 2021 | $78,000 | +4.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $75,000 | -55.9% | 1,000 | 0.0% | 0.00% | -66.7% |
| Q4 2020 | $170,000 | +21.4% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $140,000 | -12.5% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $160,000 | +63.3% | 1,000 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $98,000 | -24.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $129,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
| Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
| GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
| IMS Capital Management | 32,215 | $774,000 | 0.91% |
| Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
| Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
| BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
| SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
| Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
| Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |